Rotigotine: Difference between revisions
From SEHK Wiki
Created page with "Category: DrugsCategory: Dopaminergic Antiparkinsonian agent '''Antiparkinsonian Drug''' '''Drug class: :Category: Dopaminer..." |
No edit summary |
||
| Line 6: | Line 6: | ||
'''Rotigotine (NEUPRO)'''(中文:[[羅替戈汀]]) | '''Rotigotine (NEUPRO)'''(中文:[[羅替戈汀]]) | ||
==Common Strengths== | |||
Rotigotine is available in a transdermal patch form, which provides a continuous release of the medication over 24 hours. It is available in several strengths: | |||
*1 mg/24 hr | |||
*2 mg/24 hr | |||
*3 mg/24 hr | |||
*4 mg/24 hr | |||
*6 mg/24 hr | |||
*8 mg/24 hr | |||
==Drug Trade Names== | |||
*Neupro | |||
==Drug Usage== | |||
*Rotigotine is used for: | |||
**Treating Parkinson's disease (both early and advanced stages) | |||
**Managing moderate-to-severe primary Restless Legs Syndrome (RLS) | |||
==Mechanism of Action== | |||
Rotigotine acts as an agonist for dopamine receptors (D1, D2, D3) in the brain, which helps restore balance of dopamine, a neurotransmitter that is deficient in Parkinson's disease. It also interacts with adrenergic and serotonergic receptors, contributing to its therapeutic effects. | |||
==Route of Administration== | |||
Rotigotine is administered transdermally via a patch applied to the skin once daily. | |||
==Dosages== | |||
*Parkinson's Disease: Start at 2 mg/24 hr; may increase to a maximum of 8 mg/24 hr. | |||
*RLS: Start at 1 mg/24 hr; maximum of 3 mg/24 hr. | |||
Revision as of 01:54, 28 October 2024
Drug class: Dopaminergic Antiparkinsonian Agent
Rotigotine (NEUPRO)(中文:羅替戈汀)
Common Strengths
Rotigotine is available in a transdermal patch form, which provides a continuous release of the medication over 24 hours. It is available in several strengths:
- 1 mg/24 hr
- 2 mg/24 hr
- 3 mg/24 hr
- 4 mg/24 hr
- 6 mg/24 hr
- 8 mg/24 hr
Drug Trade Names
- Neupro
Drug Usage
- Rotigotine is used for:
- Treating Parkinson's disease (both early and advanced stages)
- Managing moderate-to-severe primary Restless Legs Syndrome (RLS)
Mechanism of Action
Rotigotine acts as an agonist for dopamine receptors (D1, D2, D3) in the brain, which helps restore balance of dopamine, a neurotransmitter that is deficient in Parkinson's disease. It also interacts with adrenergic and serotonergic receptors, contributing to its therapeutic effects.
Route of Administration
Rotigotine is administered transdermally via a patch applied to the skin once daily.
Dosages
- Parkinson's Disease: Start at 2 mg/24 hr; may increase to a maximum of 8 mg/24 hr.
- RLS: Start at 1 mg/24 hr; maximum of 3 mg/24 hr.
